Asparlas and Ethinyl estradiol and norgestrel
Determining the interaction of Asparlas and Ethinyl estradiol and norgestrel and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance. MANAGEMENT: The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.
Professional:GENERALLY AVOID: Theoretically, there is potential for an indirect interaction between asparaginase and oral contraceptives. The mechanism may involve asparaginase's hepatotoxicity, which may impair oral contraceptives' hepatic clearance.
MANAGEMENT: The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.
Generic Name: ethinyl estradiol / norgestrel
Brand name: Cryselle 28, Low-Ogestrel, Ogestrel-28, Lo/Ovral-21, Lo/Ovral-28, Ovral, Ovral-28, Low-Ogestrel-21, Ovral-21, Elinest, Cryselle-28, Ogestrel
Synonyms: Norgestrel and Ethinyl Estradiol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Asparlas-Ethinyl estradiol and segesterone vaginal ring
- Asparlas-Ethinyl Estradiol, Drospirenone, and Levomefolate
- Asparlas-Ethinyl estradiol, folic acid, and levonorgestrel
- Asparlas-Ethinyl Estradiol, Norethindrone, and Ferrous Fumarate
- Asparlas-Ethiodized oil Injection
- Asparlas-Ethiodol
- Ethinyl estradiol and norgestrel-Aspercreme Lidocaine
- Ethinyl estradiol and norgestrel-Aspergum
- Ethinyl estradiol and norgestrel-Aspir 81
- Ethinyl estradiol and norgestrel-Aspir-Low
- Ethinyl estradiol and norgestrel-Aspirin
- Ethinyl estradiol and norgestrel-Aspirin and caffeine